Hengrui Medicine's HR19034 eye drops application accepted

Jiangsu Hengrui Medicine announced that its subsidiary, Chengdu Shengdi Pharmaceutical, has received acceptance from China's National Medical Products Administration for its marketing authorization application for HR19034 eye drops. The drug is intended to slow the progression of myopia in children aged 6 to 12 with specific refractive error ranges. Clinical trials have demonstrated HR19034's effectiveness and safety, with Phase II/III trials meeting pre-defined endpoints. The announcement highlighted the growing prevalence of myopia globally, noting projections of 4.758 billion cases by 2050. The company cautioned investors about the risks inherent in drug development and commercialization, stating that the company has invested approximately RMB 50.32 million in R&D for the project. The company committed to fulfilling its information disclosure obligations.